8-K: Olema Reports Positive Phase 1 Data for Cancer Drug OP-3136

Olema Pharmaceuticals announced encouraging preliminary clinical data from its Phase 1 study of OP-3136, a KAT6 inhibitor, showing good tolerability and anti-tumor activity across multiple solid tumor types.

Summary

• Preliminary Phase 1 clinical data for OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, demonstrated acceptable tolerability and promising anti-tumor activity.
• The study evaluated OP-3136 monotherapy in 32 heavily pretreated patients with ER+/HER2advanced breast cancer (ABC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic non-small cell lung cancer (mNSCLC).
• OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed across daily doses up to 45 mg.
• Most treatment-related adverse events (TRAEs) were Grade 1 or 2, with no Grade 4 or 5 TRAEs, and no treatment discontinuations occurred due to TRAEs.
• Tumor shrinkage was observed in 13 out of 19 response-evaluable patients, with 3 partial responses (2 confirmed, 1 unconfirmed) in patients with measurable disease.
• The longest duration of treatment was 62 weeks, and 11 patients remain on treatment, including 9 with ABC and 2 with mCRPC.
• OP-3136 demonstrated rapid, sustained, and significant reduction in levels of lysine 23 of histone H3, consistent with on-target KAT6 inhibition.
• Pharmacokinetics showed predictable, dose-proportional plasma exposure, with steady-state concentrations exceeding efficacy targets based on preclinical models at doses of 6 mg and above.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, demonstrating good safety and early efficacy signals for OP-3136 in a challenging patient population, which de-risks the asset for further development.

Positives

• OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed across the evaluated daily dose range up to 45 mg per day orally.
• Most treatment-related adverse events (TRAEs) were Grade 1 or 2, with no Grade 4 or 5 TRAEs observed, and no treatment discontinuations occurred due to TRAEs.
• Evidence of anti-tumor activity was observed, with tumor shrinkage in 13 out of 19 response-evaluable patients across dose levels and tumor types.
• Partial responses were observed in 3 patients with measurable disease, including 2 confirmed partial responses and 1 unconfirmed partial response.
• The longest duration of treatment reached 62 weeks, with 11 patients remaining on treatment, indicating potential durability.
• OP-3136 demonstrated rapid, sustained, and significant on-target KAT6 inhibition, consistent with its mechanism of action.
• Pharmacokinetics were predictable and dose-proportional, with steady-state concentrations exceeding preclinical efficacy targets at doses of 6 mg and above.

Negatives

• Common treatment-related adverse events included dysgeusia (81% any grade; 56% grade 1, 25% grade 2), anemia (38% any grade; 6% grade 3), and neutropenia (34% any grade; 28% grade 3), which, while manageable, are notable side effects.
• The data is preliminary from a Phase 1 study, meaning larger, later-stage trials are required to confirm the full efficacy and safety profile.
• Only 3 partial responses were observed among 19 response-evaluable patients, which, while positive, represents a small subset of the overall cohort.

Risks

• Actual results, performance, or achievements could differ materially from forward-looking statements due to various risks and uncertainties.
• Risks and uncertainties are discussed in the section titled 'Risk Factors' in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and other filings and reports with the U.S. Securities and Exchange Commission.
• The potential beneficial characteristics, including safety, tolerability, activity, efficacy, and therapeutic effects of OP-3136, are subject to the outcomes of future clinical trials.
• The continued development and advancement of OP-3136, including its potential combinability with other therapies like palazestrant and fulvestrant, is not guaranteed and faces inherent uncertainties of drug development.

Future Outlook

The company looks forward to progressing OP-3136 in development, particularly in combination with palazestrant in metastatic breast cancer, and believes it has the potential to be a best-in-class KAT6 inhibitor and a differentiated option for difficult-to-treat cancers. The Phase 1 development will continue, evaluating OP-3136 as monotherapy and in combination with multiple agents, including fulvestrant and palazestrant.

Management Comments

• "We are pleased to share the initial Phase 1 data for OP-3136, which demonstrated acceptable tolerability and promising anti-tumor activity as a monotherapy across multiple dose levels in various advanced solid tumor types." Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
• "The decreases in tumor size observed in over two-thirds of evaluable patients and evidence of on-target engagement reinforce our confidence in OP-3136 as a potential best-in-class KAT6 inhibitor and a potentially differentiated option for difficult-to-treat cancers." Sean P. Bohen, M.D., Ph.D.
• "These initial results from the Phase 1 study of OP-3136, including confirmed and durable responses and a manageable safety profile in a heavily pretreated population, underscore the potential of KAT6 inhibition as a therapeutic strategy in different solid tumor types." Amita Patnaik, MD, FRCPC, Principal Investigator, Co-Founder, and Co-Director of Clinical Research at the START Center for Cancer Research.
• "Supported by evidence of target engagement and predictable pharmacokinetics across all doses evaluated to date, I am excited to further evaluate this novel therapy, both as a monotherapy and in combination with multiple agents, as Phase 1 development continues." Amita Patnaik, MD, FRCPC.

Industry Context

StockSavvy.ai notes that the oncology space, particularly for advanced breast, prostate, and lung cancers, remains a high-need area for novel therapies, especially for patients who have become resistant or intolerant to standard-of-care treatments. The development of targeted epigenetic inhibitors like KAT6 inhibitors represents a growing trend in precision oncology, aiming to address specific molecular pathways driving cancer growth. Positive early-stage data, particularly with a manageable safety profile and signs of efficacy in heavily pretreated patients, can position a drug candidate favorably within this competitive landscape, signaling potential for future combination therapies.

Comparison to Industry Standards

• The observed safety profile of OP-3136, with no dose-limiting toxicities and no Grade 4 or 5 TRAEs up to 45 mg/day, appears favorable compared to some highly toxic chemotherapy regimens often used in heavily pretreated advanced cancer patients.
• The demonstration of tumor shrinkage in over two-thirds of evaluable patients and partial responses in 3 patients, while preliminary, suggests a level of activity that warrants further investigation, especially given the challenging patient population resistant to prior standard treatments.
• The longest duration of treatment at 62 weeks for some patients indicates potential durability of response, which is a key metric for novel oncology agents.
• The on-target engagement and predictable pharmacokinetics are crucial for drug development, aligning with industry best practices for demonstrating a drug's mechanism of action and appropriate dosing.

Stakeholder Impact

• Shareholders: Positive preliminary clinical data could increase investor confidence and potentially lead to an increase in share price, reflecting the de-risking of a key pipeline asset.
• Patients: The promising safety and efficacy signals for OP-3136 offer hope for a new therapeutic option for patients with advanced breast, prostate, and lung cancers who have become resistant or intolerant to existing treatments.
• Medical Community: The data presentation at ASCO will inform oncologists and researchers about the potential of KAT6 inhibition and OP-3136, potentially influencing future treatment strategies and research directions.

Next Steps

• Present preliminary clinical data for OP-3136 at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026.
• Present a trial-in-progress poster for the Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib at the ASCO Annual Meeting on June 1, 2026.
• Continue Phase 1 development of OP-3136, evaluating it as a monotherapy and in combination with other agents, including fulvestrant and palazestrant.
• Further evaluate OP-3136, particularly in combination with palazestrant in metastatic breast cancer.

Key Dates

Recommendation

The preliminary Phase 1 data for OP-3136 shows a highly favorable safety profile with no dose-limiting toxicities and manageable adverse events, coupled with clear signs of anti-tumor activity (tumor shrinkage in 68% of evaluable patients, 3 partial responses) in a heavily pretreated, difficult-to-treat patient population. The on-target engagement and predictable pharmacokinetics further de-risk the asset. This positive early-stage clinical validation significantly enhances the drug's potential and the company's pipeline value, warranting a strong buy recommendation for investors seeking exposure to innovative oncology therapeutics.

Keywords

Olema Pharmaceuticals, OLMA, OP-3136, KAT6 inhibitor, Phase 1 clinical trial, breast cancer, prostate cancer, lung cancer, oncology, biopharmaceutical, clinical data, ASCO, ER+/HER2-, metastatic cancer, epigenetic therapy